Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 2 Effect of atorvastatin or bezafibrate treatment on circulating solubilized Fas ligand (sFasL) levels in patients with hyperlipidemia. Atorvastatin treatment normalized sFasL levels in hyperlipidemic patients at six (striped bars) and 12 months (solid bars). Open bars = baseline. Data are expressed as median values. *p < 0.0001 and  p < 0.0005 compared with healthy subjects.
|
